Emirelle (LARC)

A long-acting intrauterine contraceptive providing up to 5 years of protection.

Emirelle contains levonorgestrel (52 mg),  releases average 20 mcg per day locally and continuously into the uterine cavity. It acts primarily by thickening cervical mucus to inhibit sperm penetration, suppressing endometrial proliferation, and creating an environment unfavourable for implantation. Ovulation is generally preserved in most users, while systemic hormone exposure remains low due to predominant local action. 

Indication for Use 

• Long-acting reversible contraception for up to 5 years 
• Treatment of heavy menstrual bleeding (menorrhagia) 
• Endometrial protection during estrogen therapy (as clinically indicated) 

Key Advantages 

• High-dose 52 mg LNG system ensures sustained efficacy and bleeding control over 5 years 
• Up to 5 years of highly effective contraception (99.9%) 
• Significant reduction in menstrual blood loss; many users experience lighter periods or amenorrhea 
• Localized hormone delivery minimizes systemic adverse effects compared to oral therapies 
• Estrogen-free method 
• Improves quality of life in women with heavy menstrual bleeding 
• Rapid return of fertility after removal 
• Suitable for long-term use with minimal user intervention 
• Cost-effective long-term solution compared to repeated medical or surgical interventions 
• Backed by robust clinical evidence supporting both contraceptive and non-contraceptive benefits 

 (Insertion and removal must be performed by a trained healthcare professional. Does not protect against sexually transmitted infections.)